Adagene Inc (ADAG)vsAstraZeneca PLC (AZN)
ADAG
Adagene Inc
$3.32
-7.26%
HEALTHCARE · Cap: $249.75M
AZN
AstraZeneca PLC
$185.95
-1.94%
HEALTHCARE · Cap: $282.69B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 787800% more annual revenue ($60.44B vs $7.67M). AZN leads profitability with a 17.2% profit margin vs -229.6%. AZN earns a higher WallStSmart Score of 64/100 (C+).
ADAG
Avoid22
out of 100
Grade: F
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+89.5%
Fair Value
$29.40
Current Price
$3.32
$26.08 discount
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 7333.0% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -144.5% — below average capital efficiency
Negative free cash flow — burning cash
Moderate valuation
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ADAG
The strongest argument for ADAG centers on Revenue Growth, Debt/Equity. Revenue growth of 7333.0% demonstrates continued momentum.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : ADAG
The primary concerns for ADAG are EPS Growth, Market Cap, Return on Equity.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Key Dynamics to Monitor
ADAG profiles as a hypergrowth stock while AZN is a mature play — different risk/reward profiles.
ADAG carries more volatility with a beta of 0.57 — expect wider price swings.
ADAG is growing revenue faster at 7333.0% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 22/100), backed by strong 17.2% margins and 12.5% revenue growth. ADAG offers better value entry with a 89.5% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Adagene Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Adagene Inc., a clinical-stage biopharmaceutical company, is dedicated to the research, development, and production of monoclonal antibody drugs for cancer. The company is headquartered in Suzhou, China.
Visit Website →AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?